Roche reaffirms 2026 outlook for mid-single-digit sales growth at constant exchange rates
Roche reaffirmed its 2026 outlook for mid-single-digit sales growth and high-single-digit core earnings-per-share growth at constant exchange rates. Nine-month sales rose 6% to CHF 46.49 billion, while third-quarter sales increased 7% at constant exchange rates.
1. Outlook reaffirmed
Roche reaffirmed its 2026 outlook for mid-single-digit sales growth at constant exchange rates and said it targets high-single-digit growth in core earnings per share. The group aims to raise its dividend in Swiss francs again.
2. Sales growth
Nine-month sales reached CHF 46.49 billion, up 6% at constant exchange rates, driven by strong demand for medicines and diagnostics. Third-quarter sales rose 7% at constant exchange rates and 8% in Swiss francs as currency effects reversed.
